|Outcome||Multivariate analyses (statin users vs non-users)|
|HR||95% CI||p Value|
|Disease progression†||0.75||0.52 to 1.07||0.1135|
|All-cause||0.54||0.24 to 1.21||0.1369|
|IPF-related||0.36||0.14 to 0.95||0.0393|
|Absolute decrease ≥10%||0.81||0.47 to 1.40||0.4533|
|Relative decrease ≥10%||0.90||0.59 to 1.38||0.6262|
|Absolute decrease ≥5%||0.97||0.68 to 1.40||0.8805|
|Relative decrease ≥5%||0.91||0.66 to 1.25||0.5548|
|Death or absolute FVC decrease ≥10%||0.71||0.48 to 1.07||0.1032|
|Death or 6MWD decrease ≥50 m||0.69||0.48 to 0.99||0.0465|
|All-cause||0.58||0.35 to 0.94||0.0289|
|Respiratory-related‡||0.44||0.25 to 0.80||0.0063|
*Patients with missing baseline data were excluded from relevant analyses.
†Defined as ≥10% decrease in per cent predicted FVC, ≥50 m decline in 6MWD or death.
‡Hospitalisation in which the primary reason for admission was determined to be respiratory-related by a blinded clinical investigator.
6MWD, 6-minute walk distance; IPF, idiopathic pulmonary fibrosis.